Steve Scala
Stock Analyst at TD Cowen
(2.78)
# 1,728
Out of 5,127 analysts
32
Total ratings
74.07%
Success rate
13.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $41.39 | +8.72% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $233.42 | -3.61% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $56.72 | +4.02% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $95.16 | -0.17% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $108.60 | +24.31% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $25.28 | +26.58% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $1,108.09 | -54.88% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $141.98 | -26.05% | 4 | Feb 1, 2021 |
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $41.39
Upside: +8.72%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $233.42
Upside: -3.61%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $56.72
Upside: +4.02%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $95.16
Upside: -0.17%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $108.60
Upside: +24.31%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $25.28
Upside: +26.58%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $1,108.09
Upside: -54.88%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $141.98
Upside: -26.05%